Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NOX-H94 versus placebo during experimental human endotoxemia
NL-OMON35593Phase 2Active, not recruiting
- Sponsor
- TME Pharma
- Start
- Jan 2012
- Modality
- RNA Aptamers → RNA Therapeutics → Nucleic Acid Therapeutics, DNA Aptamers → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in anemia of inflammation (AI) comparing NOX-H94 with Placebo (2 arms). Primary endpoint: Change in serum iron concentration at 9 hours after LPS administration versus baseline. Started Jan 2012; status: active, not recruiting.
02
Drugs
lexaptepid pegol
03
Conditions
anemia of inflammation (AI)
Beyond the preview
Go deeper on NL-OMON35593.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON35593.